92 related articles for article (PubMed ID: 30994307)
1. One-year outcome of the everolimus-eluting, balloon-expandable Promus Element and Promus Element Plus stent in the treatment of below-the-knee lesions in CLI patients.
Taeymans K; Bosiers M; Deloose K; Callaert J; Keirse K; Verbist J; van den Eynde W; Torsello G; Wauters J
J Cardiovasc Surg (Torino); 2020 Aug; 61(4):445-450. PubMed ID: 30994307
[TBL] [Abstract][Full Text] [Related]
2. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
Bosiers M; Callaert J; Keirse K; Hendriks JMH; Peeters P; Verbist J; Maene L; Beelen R; Deloose K
J Endovasc Ther; 2017 Jun; 24(3):311-316. PubMed ID: 28351310
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease.
Bosiers M; Scheinert D; Peeters P; Torsello G; Zeller T; Deloose K; Schmidt A; Tessarek J; Vinck E; Schwartz LB
J Vasc Surg; 2012 Feb; 55(2):390-8. PubMed ID: 22169682
[TBL] [Abstract][Full Text] [Related]
4. Everolimus-Eluting Stent for Patients With Critical Limb Ischemia and Infrapopliteal Arterial Occlusive Disease.
Giaquinta A; Vincenzo A; De Marco E; Veroux M; Veroux P
Vasc Endovascular Surg; 2017 Feb; 51(2):60-66. PubMed ID: 28100126
[TBL] [Abstract][Full Text] [Related]
5. Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia.
Karnabatidis D; Spiliopoulos S; Diamantopoulos A; Katsanos K; Kagadis GC; Kakkos S; Siablis D
J Endovasc Ther; 2011 Feb; 18(1):1-12. PubMed ID: 21314342
[TBL] [Abstract][Full Text] [Related]
6. Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Arteries Below the Knee: 12-Month Clinical and Imaging Outcomes.
Varcoe RL; Schouten O; Thomas SD; Lennox AF
JACC Cardiovasc Interv; 2016 Aug; 9(16):1721-8. PubMed ID: 27539693
[TBL] [Abstract][Full Text] [Related]
7. Three-Year Results of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Infrapopliteal Arteries.
Varcoe RL; Thomas SD; Lennox AF
J Endovasc Ther; 2018 Dec; 25(6):694-701. PubMed ID: 30205736
[TBL] [Abstract][Full Text] [Related]
8. Initial clinical experience with the 4-F self-expanding XPERT stent system for infrapopliteal treatment of patients with severe claudication and critical limb ischemia.
Kickuth R; Keo HH; Triller J; Ludwig K; Do DD
J Vasc Interv Radiol; 2007 Jun; 18(6):703-8. PubMed ID: 17538131
[TBL] [Abstract][Full Text] [Related]
9. Primary use of sirolimus-eluting stents in the infrapopliteal arteries.
Rastan A; Schwarzwälder U; Noory E; Taieb FH; Beschorner U; Sixt S; Bürgelin K; Amantea P; Neumann FJ; Zeller T
J Endovasc Ther; 2010 Aug; 17(4):480-7. PubMed ID: 20681763
[TBL] [Abstract][Full Text] [Related]
10. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
[TBL] [Abstract][Full Text] [Related]
11. Outcome of a drug-eluting stent in longer below-the-knee lesions in patients with critical limb ischemia.
Bosiers MJ; Deloose K; Peeters P; Torsello G; Zeller T; Scheinert D; Schmidt A; Maene L; Keirse K; Varcoe R; Bosiers M
J Cardiovasc Surg (Torino); 2017 Feb; 58(1):49-54. PubMed ID: 27455888
[TBL] [Abstract][Full Text] [Related]
12. One-year outcome of the paclitaxel-eluting Legflow balloon catheter in the treatment of long and complex femoropopliteal lesions.
Bosiers M; Deloose K; Torsello G; Scheinert D; Verbist J; van den Eynde W; Maene L; Beelen R; Keirse K; Hendriks J; Callaert J; Bosiers M; Wauters J
J Cardiovasc Surg (Torino); 2020 Aug; 61(4):471-477. PubMed ID: 32241092
[TBL] [Abstract][Full Text] [Related]
13. One year outcome after primary stenting of infrapopliteal lesions with the Chromis Deep stent in the management of critical limb ischaemia.
Deloose K; Bosiers M; Peeters P
EuroIntervention; 2009 Aug; 5(3):318-24. PubMed ID: 19736155
[TBL] [Abstract][Full Text] [Related]
14. Endovascular treatment of popliteal artery segments P1 and P2 in patients with critical limb ischemia: initial experience using a helical nitinol stent with increased radial force.
Goltz JP; Ritter CO; Kellersmann R; Klein D; Hahn D; Kickuth R
J Endovasc Ther; 2012 Jun; 19(3):450-6. PubMed ID: 22788900
[TBL] [Abstract][Full Text] [Related]
15. Mid-Term Outcomes of Endovascular Treatment for TASC-II D Femoropopliteal Occlusive Disease with Critical Limb Ischemia.
Torres-Blanco Á; Edo-Fleta G; Gómez-Palonés F; Molina-Nácher V; Ortiz-Monzón E
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):344-52. PubMed ID: 26202389
[TBL] [Abstract][Full Text] [Related]
16. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study.
Laird JR; Yeo KK; Rocha-Singh K; Das T; Joye J; Dippel E; Reddy B; Botti C; Jaff MR
Catheter Cardiovasc Interv; 2012 Nov; 80(5):852-9. PubMed ID: 22422738
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents.
Kereiakes DJ; Windecker S; Jobe RL; Mehta SR; Sarembock IJ; Feldman RL; Stein B; Dubois C; Grady T; Saito S; Kimura T; Underwood P; Allocco DJ; Meredith IT
Circ Cardiovasc Interv; 2019 Sep; 12(9):e008152. PubMed ID: 31451014
[TBL] [Abstract][Full Text] [Related]
18. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
[TBL] [Abstract][Full Text] [Related]
19. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.
Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD
J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736
[TBL] [Abstract][Full Text] [Related]
20. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
